Variability of response to lithium augmentation in refractory depression

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Major depression is a significant global health burden.
• Treatment-resistant depression (TRD) poses a therapeutic challenge.
• Antidepressant monotherapy is often insufficient for severe cases.

Purpose of the Study:

• To evaluate the efficacy of lithium augmentation in patients with major depression refractory to standard antidepressant treatment.
• To determine the response rate and variability of lithium augmentation therapy.

Main Methods:

• A cohort of 84 patients with major depression received lithium augmentation to their existing antidepressant regimen.
• Patients underwent objective symptom ratings throughout the treatment period.
• Response was assessed at discharge or after a 24-day trial.

Main Results:

• The overall sample showed highly significant improvement in depressive symptoms.
• A marked response was observed in 31% of patients, with a partial response in 25%.
• Cumulatively, 56% of patients demonstrated a significant positive response to lithium augmentation, while 44% were nonresponders.

Conclusions:

• Lithium augmentation can be an effective strategy for a substantial proportion of patients with treatment-resistant depression.
• The response to lithium augmentation is variable, necessitating an adequate trial period.
• A minimum three-week trial of lithium augmentation is suggested to fully assess its therapeutic potential.